C ardiac hypertrophy is a common response of the heart to stress, whether internal, such as a genetic mutation, or external, such as an increased load. Cardiac hypertrophy, regardless of the etiology or ethnic background, is associated with increased morbidity and mortality, including sudden cardiac death. [1] [2] [3] Cardiac hypertrophy is also a major determinant of diastolic heart failure, a common form of heart failure particularly in the elderly. 4 Elucidation of the molecular pathogenesis of cardiac hypertrophy and its reversal through interventions could impart considerable clinical impact in a diverse array of cardiovascular diseases. 5 
Clinical Perspective p 1407
Hypertrophic cardiomyopathy (HCM) is genetic paradigm of cardiac hypertrophic response. HCM is diagnosed clinically by cardiac hypertrophy in the absence of an external cause and pathologically by myocyte hypertrophy, disarray, and interstitial fibrosis. Cardiac hypertrophy and fibrosis are major determinants of clinical outcome, including the risk of sudden cardiac death in HCM. 3, 6 The molecular genetic basis of HCM is partially known, and more than a dozen causal genes are identified. 7 Mechanistic studies point to diversity of the initial functional defects imparted by the causal mutations (reviewed in Reference 7). The functional defects encompassing changes in Ca 2ϩ sensitivity of myofibrillar ATPase activity, force generation, and actomyosin cross-bridge kinetics provide the stimulus for expression of cardiac hypertrophy (reviewed in Reference 7). Thus, cardiac hypertrophy is a secondary phenotype and therefore is potentially reversible.
To elucidate the molecular pathogenesis of HCM, we have generated ␤-myosin heavy chain (MyHC)-Q403 transgenic rabbits, which recapitulate the phenotype of human HCM. 8 -10 We have shown the potential to prevent and reverse cardiac phenotype in the ␤-MyHC-Q403 rabbits through pharmacological interventions. 11, 12 Likewise, we have shown increased levels of myocardial lipid peroxides, markers of oxidative stress, in ␤-MyHC-Q403 transgenic rabbits. 12 Moreover, we and others have implicated oxidative stress and thiol-sensitive mechanisms in the pathogenesis of fibrosis in various conditions. [13] [14] [15] However, the potential salutary effect of modulating the thio-sensitive pathways on cardiac hypertrophy, the clinical hallmark of HCM, remains to be determined. We performed a placebo-controlled study and treated the ␤-MyHC-Q403 transgenic rabbits exhibiting cardiac hypertrophy with either a placebo or N-acetylcysteine (NAC), a precursor to glutathione, the largest intracellular thiol pool, for 1 year and delineated the effects on cardiac phenotype at organ, cellular, and molecular levels.
Methods
We provide an expanded version of Methods in the online-only Data Supplement. The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health and was approved by the Institutional Animal Care and Use Committee.
␤-MyHC-Q403 Transgenic Rabbits
Adult transgenic rabbits exhibit cardiac hypertrophy, interstitial fibrosis, myocyte disarray, and preserved global systolic function but systolic dysfunction on aging, as published. 8 -10 
Placebo-Controlled Study and Administration of NAC
We treated age-, sex-, and body weight-matched adult ␤-MyHC-Q403 transgenic rabbits with either a placebo (drinking water) or NAC (500 mg/kg per day; Sigma-Aldrich, St Louis, Mo) for 12 months (nϭ10 per group). The dose was selected on the basis of prior data. 13, 14, 16 We included 10 matched nontransgenic rabbits as controls. The primary end point of the study was change in left ventricular (LV) mass corrected for body weight over the study period. The secondary end points were changes in other echocardiographic indices of cardiac hypertrophy and function as well as changes in histological phenotype.
Blood and Myocardial Levels of Oxidized and Total Glutathione
We measured plasma (nϭ6 rabbits per group) and myocardial (nϭ3 per group) levels of oxidized glutathione (GSSG) and total glutathione (reduced glutathione [GSH] plus GSSG) by a spectrophotometric method using a commercially available kit (catalog No. 371757, Calbiochem, Darmstadt, Germany) per the manufacturer's instructions.
M-Mode, 2-Dimensional, and Doppler Echocardiography
We performed and analyzed echocardiography without knowledge of the group assignment or genotypes as published. 9 -12 Myocyte Cross-Sectional Area, Collagen Volume Fraction, and Myocyte Disarray
We measured myocyte cross-sectional area, collagen volume fraction (CVF), and myocyte disarray by semiautomated planimetry in age-, sex-, and body weight-matched nontransgenic and transgenic rabbits, as published with modest modifications. 9 -12 We performed the analysis without knowledge of the genotypes and group assignment and established reproducibility by repeating the measurements in 20 to 40 randomly selected sections.
Diffusion-Weighted Magnetic Resonance Imaging
We performed diffusion-weighted magnetic resonance imaging (MRI) on 3.7% formaldehyde-perfused hearts as published. 17, 18 We calculated myofiber helix angle (␣) for a mid LV short-axis slice at 10 steps across the LV wall from epicardium to endocardium in four 20°-wide sectors at the anterior, lateral, inferior, and septal regions. We calculated the fiber angle for the entire slice as the average of these regions.
Thiol-Sensitive Signaling Kinases and Phosphatases
We determined levels of active (dephosphorylated) nuclear factor of activated T cells (NFATc) in cardiac nuclear proteins extracts by enzyme-linked immunosorbent assay. The assay is based on binding of nuclear protein extracts to oligonucleotides containing NFATc consensus binding site (5-AGGAAA-3Ј) and detection with the use of an antibody against an accessible epitope on nuclear factor of activated T cells 1 (NFATc1). We determined active cGMPdependent protein kinase (PKG) levels by enzyme-linked immunosorbent assay on the basis of detection of phosphorylation of a specific substrate. We detected and quantified expression levels of total and phosphorylated ERK 1/2, p38, and Jun N-terminal kinases (JNK) 54/46 by immunoblotting using pan-specific and phosphospecific antibodies.
Glutathiolated Cardiac ␣-Actin
We detected and quantified glutathiolation of cardiac ␣-actin by coimmunoprecipitation under nonreducing conditions. We precipitated cardiac ␣-actin in total protein extracts by adding anti-cardiac ␣-actin antibody and detected glutathiolated cardiac ␣-actin by immunoblotting using a mouse monoclonal anti-GSH antibody.
Nuclear G-Actin
We stained thin myocardial sections with a fluorescent conjugate of bovine pancreatic DNase 1, an established marker for monomeric (G) actin. 19 The sections were washed and mounted in fluorescence mounting medium containing 4Ј,6-diamidino-2-phenylindole (DAPI). We quantified the number of positively stained myocytes in 1000 myocytes per rabbit.
Subcellular Fractionation of Cardiac ␣-Actin
We extracted nuclear and cytosolic proteins per a published protocol. 20 We collected the cytosolic and nuclear protein fraction by homogenization of minced heart tissues in buffers containing 250 mmol/L and 2 mol/L sucrose, respectively, and through a series of centrifugations and filtrations. Likewise, we extracted membrane and cytoskeletal proteins through a series of homogenization of minced heart tissues and centrifugation in buffers containing NP-40 or PIPES, respectively.
Protein Degradation
We analyzed protein degradation by assessing calpains 1/2 and the 20S proteasome activities by fluorometric assays based on the detection of the fluorophore 7-amino-4-methylcoumarin (AMC). AMC is released on cleavage from Suc-LLVY-AMC in the presence of calpain-containing samples, Ca 2ϩ , and a reducing agent or in the presence of 20S proteasome and its activator (SDS). We performed the assays in the presence of specific activators and inhibitors and measured free AMC levels. We determined the proteolytic activities by subtracting the activity obtained in the presence of inhibitors from the activity detected with the activators.
Optical Mapping
We mapped the entire anterior epicardial surface of the heart using a 16ϫ16 photodiode array with a field of view of Ϸ2.7ϫ2.7 cm, as published. 17 To suppress the motion artifacts, we added excitationcontraction uncoupler 2,3-butanedione monoxime to the perfusate. We injected voltage-sensitive dye di-4-ANEPPS diluted in dimethylsulfoxide into hearts and paced the hearts. We determined the effective refractory period as the last S2 interval to capture using an S1-S2 protocol with S2 delivered at decremental intervals.
To determine the vulnerable grid, we applied a train of 20 paced beats at a basic cycle length of 300 ms followed by a truncated exponential monophasic shock at a specified coupling interval. We defined sustained arrhythmias as arrhythmias lasting Ͼ6 shock-induced extra beats. The upper and lower limits of vulnerability were the highest and lowest shock strengths to induce a sustained arrhythmia, respectively.
Statistical Analysis
We expressed the continuous variables as meanϮSD. We compared differences among the continuous variables that satisfied the normality distribution by 1-way ANOVA and applied the Bonferroni correction to multiple comparison tests. Variables that were not normally distributed were compared by Kruskal-Wallis test. We compared the differences between the baseline and follow-up continuous variables by paired t test. Differences in the categorical variables were analyzed by 2 test. All statistical analyses were performed with the use of STATA version 9.2.
The authors had full access to and take responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results

Baseline (Before Treatment) Characteristics
The data are shown in Table 1 . The mean age, body weight, and male/female ratio were similar (matched) in the experimental groups. The mean interventricular septal thickness, posterior wall thickness, LV mass, and LV mass indexed to body weight (LV mass/body weight) were greater in transgenic than in nontransgenic rabbits. We detected no significant differences in indices of cardiac hypertrophy and function, including LV fractional shortening (LVFS) between transgenic rabbits in the placebo and NAC groups before treatment.
GSSG/GSSG؉GSH Ratio
GSSG/GSSGϩGSH ratio in the blood was increased in transgenic rabbits in the placebo group by Ͼ2-fold compared with nontransgenic rabbits ( Figure 1A ). In contrast, in the NAC group, it was comparable to that in the nontransgenic rabbits but significantly less than that in the placebo group. Likewise, myocardial GSSG/GSSGϩGSH ratio was increased by 3-fold in the placebo group compared with nontransgenics ( Figure 1B ). In contrast, the ratio in the NAC group was comparable to that in the nontransgenic rabbits.
Cardiac Hypertrophy and Function
Echocardiographic indices of cardiac hypertrophy were either increased or unchanged in the placebo group at 12-month follow-up compared with baseline (Table 1) . In contrast, all echocardiographic indices of cardiac hypertrophy were regressed to normal values after 12-month treatment with NAC. LVFS was reduced significantly in transgenic rabbits in the placebo group at the follow-up (Table 1 ). In contrast, LVFS was unchanged in the nontransgenic rabbits and was modestly increased in transgenic rabbits treated with NAC. Changes in the LV end-systolic diameter were in accord with changes in LVFS. Concordant with decreased LVFS in the placebo group, mitral valve inflow E/A, an index of LV filling pressure, was increased and isovolumic relaxation time was decreased significantly ( Table 1 ). In contrast, these indices were unchanged in the nontransgenic or transgenic rabbits treated with NAC.
Myocyte Hypertrophy and Interstitial Fibrosis
Corroborating the echocardiographic indices of cardiac hypertrophy, myocyte cross-sectional area was increased by Ϸ20% in transgenic rabbits in the placebo group compared with the nontransgenic group (Figure 2) . In contrast, myocyte cross-sectional area in the NAC group was comparable to that in the nontransgenic rabbits. The mean number of myocytes per each microscopic field (ϫ400) was lower in the placebo group compared with nontransgenic rabbits or the NAC group ( Figure  2 ). The reproducibility of the measurements of myocyte crosssectional area, determined by calculating the intraobserver variability, was 3.5%. The correlation between the first and second measurements of myocyte cross-sectional area was 0.881.
CVF was increased by Ϸ3-fold in the placebo group compared with the nontransgenic group (Figure 2) . CVF was normal in rabbits treated with NAC. We tested the reproducibility of the measurements in 2 independent settings. The correlation and the mean difference between the 2 independent measurements were 0.94 and 0.20%, respectively (intraobserver variability, 2.29%).
Myocyte Disarray and Myofiber Angle Orientation
Myocyte disarray comprised Ϸ6% of the myocardium in the nontransgenic rabbits. It was increased by Ϸ3-fold in the placebo and NAC groups (15% and 18%, respectively; Figure  2 ). The correlation and the mean difference between the 2 independent measurements were 0.79 and 1.2%.
To complement the results of histological assessment of myocyte disarray, we determined myofibrillar ␣-helical angle by diffusion-weighted MRI (Figure 3 ). At the endocardium, myofiber orientation diverged between the transgenic and nontransgenic rabbits but not between the transgenic rabbits in the placebo and NAC groups (Pϭ0.036). However, myofiber ␣-helix angle at the epicardium differed modestly between transgenic rabbits in the placebo and NAC groups (Pϭ0.074). The overall fiber orientation angle differed only between the nontransgenic and transgenic rabbits in the placebo group (Pϭ0.039) but not between placebo and NAC groups.
Myocardial Levels of Selected Thiol-Sensitive Signaling Kinases and Phosphatase
To gain insight into molecular mechanisms of the beneficial effects of NAC, we determined myocardial levels of selected thiol-sensitive signaling molecules. Protein threonine phosphatases are thiol-sensitive proteins. 21 We measured myocar- Relative levels of oxidized to total glutathione (GSSG/GSHϩGSSG). A and B show the ratio of oxidized to total glutathione in the blood (nϭ6) and ventricular tissues (nϭ3), respectively. GSSG/GSHϩGSSG ratio was increased significantly in the blood and in the heart tissues in the ␤-MyHC-Q403 transgenic rabbits in the placebo group compared with nontransgenic (NTG) rabbits. In contrast, the ratio was normal in transgenic rabbits treated with NAC.
dial levels of dephosphorylated NFATc1, a downstream signal transducer of protein phosphatase 2A calcineurin. 22 We detected 64% increase in active NFATc1 levels in the placebo group compared with nontransgenic rabbits ( Figure 4A ). Myocardial levels of NFATc1 in the NAC group were comparable to levels in the nontransgenic group but 2-fold lower than levels in the placebo group. Likewise, myocardial levels of PKG, a cysteine redox sensor known to be activated by oxidative stress, 23 were increased by Ϸ80% in the placebo group compared with the nontransgenic group (PϽ0.001). Myocardial levels of active PKG were normal in rabbits treated with NAC and comparable to nontransgenic controls ( Figure 4B ).
Myocardial levels of phospho-p38 kinase were increased in the transgenic rabbits in the placebo group but were normal in the NAC-treated group ( Figure 4C and 4D ). There were modest changes in myocardial levels of phosphorylated ERK1/2 and JNK 54/46 among the groups (data not shown).
Glutathiolation of Cardiac ␣-Actin
Cytoskeletal proteins, particularly ␣-actin, are subject to glutathiolation, a modification that could affect cell cytoskeletal organization and mobility, actin polymerization, and its nuclear localization. 24 Myocardial levels of glutathiolated cardiac ␣-actin were lower by 35% in the placebo group compared with nontransgenic rabbits but were normal in the NAC-treated rabbits ( Figure 5 ), which paralleled changes in the GSSG/GSSGϩGSH ratio.
Nuclear G-Actin
Because glutathiolation of actin could affect polymerization of monomeric (G) actin to F-actin and because G-actin interacts with prohypertrophic serum response factor, 25, 26 we determined the effects of NAC on nuclear localization of G-actin ( Figure 5C ). The percentage of positively stained myocytes was not significantly different among the groups (nontransgenic, 0.75Ϯ0.20%; placebo, 0.69Ϯ0.13%; NAC, 0.81Ϯ0.21%; Pϭ0.676).
Subcellular Localization of Cardiac ␣-Actin
To determine whether glutathiolation of ␣-actin altered subcellular localization of ␣-actin, we detected levels of cardiac ␣-actin in cytosolic, nuclear, membrane, and cytoskeletal protein extracts by immunoblotting. There were modest but not nonsignificant differences in ␣-actin levels in each subcellular fraction among the groups ( Figure 5D , 5E, 5F and Figure I in the online-only Data Supplement).
Protein Degradation
Because proteolytic activities of proteasome and cysteine proteases are also influenced by reduced sulfhydryls, 27 we measured activities of calpains 1 and 2 and 20S proteasome in the Myofiber ␣-helical orientation as determined by diffusion-weighted (tensor) MRI. A, Representative cross-sectional images at mid ventricular levels are shown. Significant differences in myofiber orientation between transgenic rabbits in the placebo group and nontransgenic (NTG) rabbits at the endocardium and between the transgenic rabbits in the placebo and NAC groups at the epicardium are noted. B, Diagrammatic representation of myofiber ␣-helical orientation from epicardium to endocardium. C, Quantitative fiber orientation at mid ventricle is plotted against transmural depth from endocardium (Endo-) to epicardium (Epi-) to illustrate the differences among the 3 groups. WT indicates wild-type; TG, transgenic. D, Overall mean myofiber ␣-helical angles among the 3 groups.
p-p38
Total-p38 Relative levels of p-p38 (fold) The upper blot in C shows phosphorylated p38 (p-p38) levels in the myocardium and the lower blot levels of total p38 levels, detected by immunoblotting. D shows quantitative levels of phospho-p38 as determined by densitometry and normalized to that in the nontransgenic group. In all panels, means and SDs are shown. The probability values at the top of each panel represent differences among the 3 groups. The Bonferroni adjusted probability values for paired groups are shown (nϭ4 rabbits per group in each set of experiments).
myocardial extracts. We detected no significant differences in activity levels of 20S proteosome or calpains 1 and 2 among the groups ( Figure II in the online-only Data Supplement).
Reduced Vulnerability to Ventricular Arrhythmias
To determine the potential effects of regression of cardiac hypertrophy on arrhythmogenic propensity, we determined vulnerability to ventricular arrhythmias by optical mapping. The upper limits of vulnerability of both ventricles were increased by Ϸ2-fold in the placebo group compared with the nontransgenic group, but the lower limits were unchanged ( Table 2 ). The upper limits of vulnerability, vulnerable window, and vulnerable period were significantly lower in the NAC group compared with placebo ( Figure 6A and 6B). NAC had no detrimental effects on any of the electrophysiological parameters measured.
Discussion
We showed that long-term treatment with NAC, a precursor to the most abundant intracellular nonprotein thiol pool against oxidative stress, 28 reversed cardiac and myocyte hypertrophy and interstitial fibrosis, prevented LV systolic dysfunction, and improved arrhythmogenic propensity in an established transgenic rabbit model of human HCM. 8 -10,12 Reversal of the phenotype was associated with normalization of levels of oxidized glutathione; glutathiolated cardiac ␣-actin; and thiol-sensitive molecules active PKG, calcineurin target NFATc1, and phospho-p38. Treatment with NAC did not affect myocyte or myofibrillar organization or subcellular localization of ␣-actin and G-actin. The antifibrotic effect of NAC is in accord with the findings in other models and organs. 13,29 -33 Resolution of cardiac and myocyte hypertrophy and prevention of cardiac systolic dysfunction with NAC are novel findings. The data suggest the potential beneficial effects of this safe prodrug in reversal of cardiac phenotype in HCM and prevention of global cardiac systolic dysfunction. NAC provides the cysteine necessary for GSH synthesis. Accordingly, glutamate cysteine ligase (␥-glutamylcysteine synthetase) catalyzes binding of cysteine to glutamate to generate ␥-glutamylcysteine. Then glutathione synthetase catalyzes binding of glycine to ␥-glutamylcysteine to generate GSH (␥-glutamylcysteinylglycine). The transfer of glutamate from GSH to other amino acids by the ␥-glutamyl transpeptidase and subsequent catalysis of cysteinylglycine dipeptide to cysteine and glycine by a dipeptidase completes the cycle of synthesis and metabolism. Glutathione reductase catalyzes the recycling of reduced glutathione from oxidized glutathione. NAC by providing cysteine replenishes GSH, which is usually depleted in disease states, as was also found in the ␤-MyHC-Q403 rabbits. The finding is in accord with our previous data showing increased levels of markers of oxidative stress in this model. 12 Increased GSSG/ GSSGϩGSH in the ␤-MyHC-Q403 rabbits was associated with changes in activities of selected thiol-sensitive kinases and calcineurin phosphatase involved in cardiac hypertrophy and function. A notable effect of NAC was reduction of prohypertrophic dephosphorylated NFATc1 levels, which provides a plausible molecular mechanism for the antihypertrophic and antifibrotic effects of NAC. 22 Likewise, myocardial levels of PKG, a cysteine-redox sensor activated on exposure to oxidative stress, 23 were increased in the placebo group but were normal in the NAC group. Reduced myocar- dial levels of phospho-p38 in the NAC group are consistent with the known inhibitory effect of NAC on p38 activity. 13, 28 The changes in levels of active PKG and phospho-p38 may simply reflect the xidative state of the myocardium but necessarily mediate the beneficial effects of NAC on cardiac structure and function. The findings also do not exclude involvement of alternative mechanisms for the salutary effects of NAC in our HCM model. Given the complexity of the molecular biology of cardiac hypertrophy, fibrosis, and dysfunction, the effects could encompass multiple independent and interactive pathways, including transcriptional regulation of gene expression and posttranslational thiol modification of cysteines at the surface of numerous kinases, phosphatases, and sarcomeric proteins. Actin is a redox-sensitive protein, known to be glutathiolated via formation of a mixed disulfide between cysteine residues and glutathione. 24 The modification is considered essential for its polymerization, cytoskeleton organization, formation of stress fibers, and cell spreading. 24, 25 Monomeric or G-actin is an important regulator of the prohypertrophic serum response factor. 26, 34 Levels of glutathiolated cardiac ␣-actin, in accord with increased GSSG/GSSGϩGSH, were reduced in the placebo group. However, we found no significant changes in nuclear G-actin levels, a potential antihypertrophic molecule. Thus, the antihypertrophic effect of NAC was independent of nuclear localization of G-actin and serum response factor. 26, 34 However, experiments in an in vivo model wherein the stimulus for induction of the phenotype is chronic and modest, compared with in vitro studies, may not offer sufficient resolution to substantiate the biological significance of glutathiolated cardiac ␣-actin in regression of cardiac phenotype in HCM.
The attractiveness of NAC as a potential therapy for HCM and heart failure is emphasized by its well-established safety profile in humans, even at doses as high as 8 g/d. 35, 36 The well-established safety of NAC, along with the convenience of administration and the plurality of its beneficial effects at organ, cellular, and molecular levels, renders NAC a highly attractive therapeutic option for cardiomyopathies. The clinical significance of the findings is highlighted by the fact that there is currently no effective pharmacological therapy for HCM and in general for cardiac hypertrophy. Nonetheless, the findings could be restricted to our specific animal models or the specific mutations and may not be applicable across the spectrum of human HCM. We did not observe a discernible side effect. However, a recent study reported a higher pulmonary artery pressure in mice treated with NAC. 37 In contrast, several studies have shown the beneficial effects of NAC in improving pulmonary artery hypertension. 32, 33, 38 Moreover, NAC has been used in humans to treat various conditions including idiopathic pulmonary fibrosis without reports of pulmonary hypertension as a side effect. 29 We did not measure pulmonary artery pressure in our rabbits but did not notice changes in pulmonary artery or right ventricular size and function on echocardiograms.
In summary, we have shown that long-term treatment with NAC, a precursor to the most abundant intracellular defense mechanism against oxidative damage, reverses established cardiac hypertrophy and fibrosis, prevents cardiac dysfunction, and reduces susceptibility to ventricular arrhythmia in the ␤-MyHC-Q403 transgenic rabbit model of human HCM. The beneficial effects were associated with favorable changes in myocardial levels of selective thiol-sensitive kinases and phosphatases. The findings raise the potential utility of NAC for treatment of human HCM, a most common discernible cause of sudden cardiac death in the young and a major cause of mortality and morbidity in the elderly. 6 Because cardiac hypertrophy and fibrosis are common and important determinants of clinical outcomes in various cardiovascular diseases, the findings could have broader implications. Finally, the effect of NAC on prevention of systolic dysfunction signals its potential utility in prevention and treatment of systolic heart failure. Collectively, the findings provide the prerequisite for testing the potential salutary effects of NAC in treatment and prevention of HCM and heart failure in humans.
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CLINICAL PERSPECTIVE
Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by primary cardiac hypertrophy. Cardiac hypertrophic and accompanying fibrosis are major determinants of clinical outcomes, including the risk of sudden cardiac death, not only in patients with HCM but also in patients with various cardiovascular diseases. Current pharmacological agents are not known to reverse established cardiac hypertrophy and fibrosis in patients with HCM. We and others have proposed that cardiac hypertrophy and fibrosis in HCM are secondary to activation of various stress-responsive signaling and trophic molecules, including oxidative stress-responsive molecules. Hence, cardiac hypertrophy and fibrosis are potentially reversible. We show in a transgenic rabbit model of human HCM that long-term treatment with N-acetylcysteine (NAC), a precursor of glutathione, the largest intracellular thiol pool against oxidative stress in the body, reverses established cardiac hypertrophy and fibrosis. We show that treatment with NAC also prevents deterioration of cardiac systolic function and reduces susceptibility to arrhythmias. We document the beneficial effects of NAC at molecular, cellular, and whole organ levels and illustrated putative molecular mechanisms. The findings suggest the potential utility of NAC in treatment of patients with HCM, a major cause of sudden cardiac death in the young and an important determinant of morbidity in the elderly. Because cardiac hypertrophy, fibrosis, and systolic dysfunction are common to various cardiovascular diseases, the findings could have broader clinical implications. Clinical studies are needed to determine the potential beneficial effects of NAC in prevention and treatment of HCM and heart failure in humans. 
MATERIAL AND METHODS
The investigation conforms to the Guide for the Care and Use of Laboratory Animals
Placebo-controlled study and administration of N-acetylcysteine (NAC):
The study groups included age-sex-and body weight-matched adult non-transgenic rabbits (N=10), β-MyHC-Q403 transgenic rabbits assigned to a placebo (drinking water, N=10) and β-MyHC-Q403 transgenic rabbits treated with NAC at the dosage of 500mg/Kg (N=10). We Measurement of blood and myocardial levels of oxidized and total glutathione: We measured levels of oxidized glutathione (GSSG) and of total glutathione [reduced glutathione (GSH) plus GSSG) in the whole blood by a spectrophotometric method using a commercially available kit (Calbiochem, EMD Chemicals Inc., affiliate of Merck KGaA, Darmstadt, Germany, cat#371757) per manufacturer's instructions (N=6 rabbits per group). In brief, we first converted all glutathione molecules in the sample to GSH by adding the enzyme glutathione reductase and nicotinamide adenine dinucleotide phosphate (NADPH). Then, we added 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) to the reaction, which in the presence of GSH forms 5-thio-2-nitrobenzoic acid (TNB), a product that is quantifiable by spectrophotometry. We then determined TNB levels by measuring the absorbance at 412 nM. We recorded the change in adsorbance for 3 minutes and calculated the rate of TNB production, which is directly proportional to the concentration of GSH in the sample.
To quantify GSSG levels, we removed the GSH in the sample by adding 1-methyl-2-vinylpyridinium trifluoromethane-sulfonate (M2VP). M2VP rapidly scavenges GSH by forming a stable complex. Then, we reduced GSSG to GSH and measured the GSH levels as described above.
Likewise, we measured myocardial levels of oxidized and total glutathione in 50 mg aliquots of freshly isolated ventricular tissues using the above kit. We homogenized the tissues in 250 µl of lysis buffer and added 10% M2PV to the lysis buffer to scavenge the GSH when measuring GSSG. We collected the supernatant and added equal volume of deproteination reagent (5% Metaphosphoric Acid; MPA). We used 50 µL of the mixture in the assay.
M mode, two dimensional and Doppler echocardiography: We performed echocardiography using a H-P Sonos 5500 unit equipped with a 8MHz transducer as To quantify CVF, we stained formalin-fixed 5-µm-thick sections with collagen-specific Sirius red F3BA. We quantified percent of positive stained areas in approximately 240 high magnification fields per each heart (N=6 per group). We excluded perivascular and epimysial collagens from the analysis. We also determined intra-observer variability of the measurement of CVF by repeating the measurements in 20 randomly selected thin myocardial sections on two different occasions.
We quantified percent of myocyte disarray as described previously 2;6;7 . We divided thin H & E stained myocardial sections into 48 fields of approximately equal size, and scored the presence or absence of disarray in each field. We computed the number of fields showing disarray in each section as a percent of the total number of fields in a total of 480 fields per heart (N=6 per group). We excluded areas of the myocardium at the junctions of interventricular septum with the ventricles, sections near the blood vessels, trabeculations and the papillary muscles from the analysis. To test the reproducibility of quantification of myocyte disarray, we quantified the percent of myocyte disarray in 40 randomly selected thin myocardial sections without knowledge of the group assignment in 2 different occasions.
Diffusion-Weighted Magnetic Resonance Imaging (DTMRI):
We performed DTMRI on 3.7% formaldehyde-perfused hearts as published recently 9;10 . In brief, we calculated myofiber helix angle (α) for a mid left ventricular short axis slice at 10 steps across the left ventricular wall from epi-to endocardium in four 20°-wide sectors at the anterior, lateral, inferior, and septal regions. We then calculated the fiber angle for the entire slice as the average of these four regions (N=4 per group). Nuclear G-actin: To detect and localize G-actin, we stained thin myocardial sections with DNase 1, which is known to preferentially bind to monomeric (G) actin as opposed to F-actin (N=4 per group) 11 . In brief, thin frozen heart sections were stained with a fluorescent conjugate of bovine pancreatic DNase I at 15 µg/ml concentration for one hour at room temperature (Alexa Fluor 594, Molecular Probes Inc., Eugene, OR, cat #D12372).
Thiol
The sections were then washed and mounted in Fluorescence Mounting Medium containing 4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, cat #H1500).
Subcellular fractionation of cardiac α-actin: To determine whether glutathiolation of cardiac α-actin affected subcellular localization of actin, we extracted nuclear and cytosolic proteins per a published protocol 12 . In brief, we performed all steps for protein extraction at 4°C, unless specified. We homogenized 200 mg aliquots of minced heart tissues in pre-chilled dounce glass tubes in ice-cold 250-STMDPS buffer [250 mM sucrose, 50 mM Tris-HCl (pH 7.4), 5 mM MgCl 2 , 1 mM DTT plus proteinase inhibitors cocktail, (cat # 11-697-498-001, Roche Diagnostics, GmbH, Mannheim, Germany)]. We centrifuged the homogenates at 800g for 15 min to collect the supernatant (cytosolic I) and repeated the steps to collect the supernatant again (cytosolic II). We centrifuged cytosolic I
and II fractions at 6,000 g for 15 min to pellet the mitochondria. We then combined the two supernatants, centrifuged it at 22,000 g for 1 hour and collected the new supernatant as cytosolic proteins fraction.
To collect nuclear proteins, we resuspended the pellets from the above steps in 300 We extracted membrane and cytoskeletal proteins using a commercially available kit (Chemicon Int., Danvers, MA; cat #2145). In brief, we homogenized aliquots of 100 mg of minced heart tissues in dounce glass homogenizers in 5 volumes of a cold buffer containing HEPES (pH7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, Sodium OrthoVanadate plus protease inhibitors cocktail. After incubation for 20 min with gentle rocking, we centrifuged the homogenates at 18,000g for 20 min to pellet membranes, nuclei and cytoskeletal fractions.
We separated the nuclei from membrane and cytoskeletal proteins by resuspending the pellets in 100 µl of an ice cold buffer containing HEPES (pH7.9), MgCl 2 , NaCl, EDTA, We determined the proteolytic activities by subtracting the activity obtained using the inhibition buffer from the activity detected with the activation buffer.
Optical Mapping Experiments:
We performed the optical mapping experiments as we published recently 9 . We used a 16 x 16 photo-diode array with a field-of-view of approximately 2.7 x 2.7 cm to map the entire anterior epicardial surface of the heart. We added the excitation-contraction uncoupler 2,3-butanedione monoxime (BDM, 15mM; Fisher Scientific, Fair Lawn, NJ) to the perfusate in order to suppress the motion artifacts. We then injected voltage-sensitive dye di-4-ANEPPS (Molecular Probes, Eugene, OR) diluted in dimethylsulfoxide (Sigma Aldrich, Inc., St. Louis, MO) into hearts (1.25 mg/ml). We paced the hearts from the anterior left ventricular epicardium midway between the apex and base at a current at least 4 times higher than the pacing threshold. We used an S1-S2 protocol comprised of 20 S1s delivered at a cycle length of 300 ms and S2s with decremental intervals and defined the effective refractory period (ERP) as the last S2 interval to capture.
To determine the vulnerable grid, we applied a train of 20 paced beats at a basic cycle length of 300 ms followed by a truncated exponential monophasic shock (10 ms duration, 80% tilt) at a specified coupling interval (CI) that was randomized within the vulnerable grid. Shock strengths (SS) ranged from approximately 1 V/cm to 18 V/cm. The CI from the last paced beat ranged from 40 to 220 ms with 20 ms steps. We completed the by guest on February 21, 2013 http://circ.ahajournals.org/ Downloaded from 790501-R4 11 vulnerable grid for both shock polarities. We used a definition of sustained arrhythmias as arrhythmias lasting more than 6 shock-induced extra-beats. The upper and lower limits of vulnerability (ULV and LLV, respectively) were the highest and lowest SS at which a sustained arrhythmia was induced, respectively. The vulnerable window (VW) was the ULV minus the LLV. The longest and shortest intervals of the vulnerable period (VP) were the longest and shortest CIs which produced a sustained arrhythmia. The VP was the longest minus the shortest extent of VP.
Statistical analysis:
We expressed the continuous variables as mean ± SD and determined variance equality or homogeneity by Bartlett's test. We compared the differences among the non-parametric variables with equal variances among the three experimental groups by analysis of variance followed by pair wise comparisons (Bonferroni method). We compared the differences between the baseline and follow up non-parametric parameters by paired t test. We analyzed the differences in the parametric variables among the three groups by the Chi Square test.
OnlineSupplementaryTable1
EchocardiographicPhenotypeattheBeginning 
